Pediatrix Medical Group, Division of Neonatology, Department of Pediatrics, Greenville Memorial Hospital, Greenville, SC, USA.
J Perinatol. 2010 Dec;30(12):800-4. doi: 10.1038/jp.2010.37. Epub 2010 Mar 18.
The purpose of this study was to evaluate the demographic characteristics and outcomes of neonates who were admitted to a neonatal intensive care unit and treated with inhaled nitric oxide (iNO) during the years 2000-08. The goal of studying this group of neonates was to evaluate how iNO use has evolved in infants and to estimate the frequency of off-label use of this drug in this population.
Retrospective review of the Pediatrix Clinical Data Warehouse de-identified data set. Pediatrix Medical Group provides intensive care services in 244 hospitals in 32 states and Puerto Rico. Nine (3.7%) centers provide extracorporeal membrane oxygenation.
There were 494 255 neonates in the data set; 4316 (0.9%) were treated with iNO. The use of iNO increased from 154 of 32 967 patients in 2000 to 921 of 75 911 patients in 2008; a 2.6-fold increase (0.47 to 1.23%). There were 155 872 infants <34 weeks estimated gestational age discharged between 1 January 2000 and 31 December 2008; 1656 (1.1%) were treated with iNO. Since approval in 2000, the reported use of iNO in neonates <34 weeks increased from 0.3 to 1.8% in 2008; a sixfold increase in the reported use of iNO. The biggest increase occurred in infants between 23 and 26 weeks' gestational age (0.8 to 6.6%). In contrast, the increase in iNO use among neonates born ≥34 weeks has only increased from 0.5 to 1%.
The use of iNO has increased and the greatest increase has been the off-label use among preterm neonates.
本研究旨在评估 2000-08 年间入住新生儿重症监护病房并接受吸入一氧化氮（iNO）治疗的新生儿的人口统计学特征和结局。研究这组新生儿的目的是评估 iNO 在婴儿中的使用如何演变，并估计该药物在该人群中的超适应证使用频率。
回顾性分析 Pediatrix 临床数据仓库去识别数据集。Pediatrix 医疗集团在 32 个州和波多黎各的 244 家医院提供重症监护服务。其中 9 个（3.7%）中心提供体外膜氧合。
该数据集中共有 494255 名新生儿；4316 名（0.9%）接受 iNO 治疗。iNO 的使用从 2000 年的 32967 名患者中的 154 例增加到 2008 年的 75911 名患者中的 921 例；增加了 2.6 倍（0.47 至 1.23%）。2000 年 1 月 1 日至 2008 年 12 月 31 日期间，有 155872 名<34 周估计胎龄的婴儿出院；其中 1656 名（1.1%）接受 iNO 治疗。自 2000 年批准以来，在<34 周的新生儿中，iNO 的报告使用率从 2008 年的 0.3%增加到 1.8%；iNO 的报告使用率增加了六倍。增长最大的是 23-26 周胎龄的婴儿（0.8%至 6.6%）。相比之下，在≥34 周出生的新生儿中，iNO 的使用增加仅从 0.5%增加到 1%。
iNO 的使用有所增加，最大的增加是早产儿的超适应证使用。
